ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO731

Race Independent eGFR Equations in Assessing Renal Function in Patients With Liver Disease

Session Information

Category: Diversity and Equity in Kidney Health

  • 800 Diversity and Equity in Kidney Health

Authors

  • Meeusen, Jeff W., Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, Minnesota, United States
  • Dasari, Surendra, Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, Minnesota, United States
  • Lieske, John C., Mayo Clinic Department of Laboratory Medicine and Pathology, Rochester, Minnesota, United States
  • Lemoine, Sandrine, Department Néphrologie, Dialyse, Hypertension et Exploration Fonctionnelle Rénale, Groupement Hospitalier Eduard Herriot, Hospices Civiles de Lyon, Université Claude Bernard, Lyon, France
  • Dubourg, Laurence, Department Néphrologie, Dialyse, Hypertension et Exploration Fonctionnelle Rénale, Groupement Hospitalier Eduard Herriot, Hospices Civiles de Lyon, Université Claude Bernard, Lyon, France
  • Stämmler, Frank, Numares AG, Regensburg, Germany
  • Schiffer, Eric, Numares AG, Regensburg, Germany
Background

Renal impairment is commonly associated with liver disease, and the degree of renal dysfunction impacts decisions regarding drug dosing, therapeutic interventions, and suitability for liver transplantation. Altered hemodynamics in liver disease often result in overestimation of glomerular filtration rate (GFR) by creatinine based GFR estimating equations. Recently, we have analytically and clinically validated a novel GFR estimation equation based on serum myoinositol, valine, and creatinine quantified by nuclear magnetic resonance spectroscopy in combination with cystatin-C, age and sex (AXINON® GFR(NMR)). We hypothesized that AXINON® GFR(NMR) (GFRNMR) could improve CKD classification in the setting of liver disease.

Methods

We compared GFR estimation equations in a multicenter retrospective study of patients (n=203) with liver disease and renal tracer clearance measured GFR (mGFR). Stored serum was analyzed and used to estimate GFR based on GFRNMR, CKD-EPI 2021 eGFRcr-cys, and CKD-EPI 2021 eGFRcr.

Results

eGFRcr overestimated mGFR with a mean bias of 7.5 [4.9 - 9.8] mL/min/1.73m2 compared to a smaller bias of -2.9 [-4.8 - -1.3] for eGFRcr-cys and -1.64 [-3.43 - 0.16] for GFRNMR (both p<0.001). P30 was similar in GFRNMR and eGFRcr-cys (83% [79 - 89] and 86% [81 - 90]) but lower for eGFRcr (74% [68 – 80]). P15 was highest for GFRNMR at 59% [53 - 65] compared to 47% [40 - 53] for eGFRcr and 54% [47 - 61] for eGFRcr-cys. Concordant classification by mGFR CKD stage was 104 (51%), 109 (54%), and 120 (59%), for eGFRcr, eGFRcr-cys, and GFRNMR respectively (GFRNMR vs. eGFRcr: p = 0.074; GFRNMR vs. eGFRcr-cys: p = 0.138; eGFRcr vs. eGFRcr-cys: p = 0.588).

Conclusion

Our findings confirm that the new 2021 eGFRcr equation overestimates GFR among patients with liver disease, presumably due to reduced muscle mass. Addition of myoinositol and valine improved correlation of GFRNMR with mGFR and accurately stratified liver disease patients into CKD stages.